Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Phase 2
120
about 2.8 years
18+
16 sites in CA, FL, IL +5
What this study is about
Researchers are testing whether lutikizumab or risankizumab, a treatment, can help people with active psoriatic arthritis. The trial will last 1025 days and involve around 120 adults at various locations worldwide. Participants will receive regular checkups to monitor the effects of the treatment and any side effects.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lutikizumab
- 2.Take Risankizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody, risankizumab
Primary: Number of Participants With Adverse Events (AEs)
Dermatology